MA (EU) number 
(Invented) 
name 
Strength 
Pharmaceutical 
Form 
Route of 
Administration 
Immediate 
Packaging 
Content 
(concentration) 
Pack size 
--¹ 
--¹ 
--¹ 
--¹ 
--¹ 
--¹ 
--¹ 
Suspension for 
injection 
Suspension for 
injection 
Suspension for 
injection 
Suspension for 
injection 
Suspension for 
injection 
Suspension for 
injection 
Suspension for 
injection 
Intramuscular use  vial (glass) 
0.5 ml 
10 vials  
Intramuscular use  pre-filled syringe 
0.5 ml 
1 pre-filled syringe  
(glass) 
Intramuscular use  pre-filled syringe 
0.5 ml 
Intramuscular use  pre-filled syringe 
0.5 ml 
(glass) 
(glass) 
Intramuscular use  pre-filled syringe 
0.5 ml 
(glass) 
Intramuscular use  pre-filled syringe 
0.5 ml 
Intramuscular use  pre-filled syringe 
0.5 ml 
(glass) 
(glass) 
10 pre-filled 
syringes  
1 pre-filled syringe 
+ 1 needle  
10 pre-filled 
syringes + 10 
needles  
1 pre-filled syringe 
+ 2 needles  
10 pre-filled 
syringes + 20 
needles  
EU/1/13/828/001 
Hexacima   
EU/1/13/828/002 
Hexacima   
EU/1/13/828/003 
Hexacima   
EU/1/13/828/004 
Hexacima   
EU/1/13/828/005 
Hexacima   
EU/1/13/828/006 
Hexacima   
EU/1/13/828/007 
Hexacima   
--¹  One dose1 (0.5 mL) contains: 
Diphtheria Toxoid 
Tetanus Toxoid 
Bordetella pertussis antigens 
Pertussis Toxoid 
Filamentous Haemagglutinin 
Poliovirus (Inactivated) 
Type 1 (Mahoney) 
Type 2 (MEF-1) 
Type 3 (Saukett) 
Hepatitis B surface antigen 
Haemophilus influenzae type b polysaccharide 
(Polyribosylribitol Phosphate) 
conjugated to Tetanus protein 
1 Adsorbed on aluminium hydroxide, hydrated (0.6 mg Al3+) 
not less than 20 IU (30 Lf) 
not less than 40 IU (10 Lf) 
25 micrograms 
25 micrograms 
29 D-antigen units 
7 D-antigen units 
26 D-antigen units 
10 micrograms 
12 micrograms 
22-36 micrograms 
1 
 
 
 
 
 
 
 
 
 
 
 
2 
 
 
 
